GSK, Pfizer RSV vaccine sales fall in US
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.
GSK RSV vaccine data suggest protection across 3 seasons
The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US as Millions Fewer People Line Up
A GSK spokesperson said 9 million Americans, or two-thirds of the market, have been vaccinated against RSV with Arexvy and that the company sees opportunities for strong growth in
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV,
U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report
Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine. Read more here.
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...
GSK RSV shot 43% effective against severe disease in third year
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
McKnight's Long-Term Care News2d
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
FiercePharma2d
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...
GSK Arexvy protects from RSV over three full seasons
GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...
ENDPOINTS NEWS2d
GSK's RSV vac­cine Arexvy shows long-term pro­tec­tion in Phase 3 tri­al
GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...
GSK Says RSV Vaccine Arexvy Showed Positive Efficacy Data Over Three Seasons
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV ...